Home›Oncology› Multimodal strategies including bevacizumab and advanced radiotherapy techniques manage radiation-induced brain necrosis
Multimodal strategies including bevacizumab and advanced radiotherapy techniques manage radiation-induced brain necrosisNew strategies help manage radiation-induced brain tissue damage
Frontiers in MedicinePublished June 30, 2026DOI ↗Editorial oversight: Dr. Julia Lee, PhD · Oncology, Genomics & Drug Development
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Consider a multimodal approach including bevacizumab and refined radiotherapy to manage radiation-induced brain necrosis.
This narrative review synthesizes current knowledge regarding the pathogenesis, prevention strategies, and treatment options for radiation-induced brain necrosis (RBN) in patients with intracranial and head and neck malignancies. The scope includes a review of vascular injury mechanisms, neuroinflammation, and various management modalities.
The authors identify key pathogenic drivers including endothelial damage and HIF-1α/VEGF dysregulation, alongside microglial activation and cytokine release. Prevention strategies involve refined radiotherapy techniques such as IMRT, fSRS, and FLASH, along with pharmacological prophylaxis like bevacizumab and other neuroprotective agents. Treatment options include corticosteroids, bevacizumab, hyperbaric oxygen therapy (HBOT), laser interstitial thermal therapy (LITT), and CSF1R inhibitors.
A limitation of this review is its narrative format, which provides an overview of existing literature rather than primary clinical trial data. The evidence highlights the importance of advanced imaging for early detection, including MRS, PWI, and PET/CT. These findings provide a summary of current understanding and management guidelines for RBN in patients undergoing radiotherapy.
How this fits prior evidence
This narrative review addresses a gap in the management of radiation-induced brain necrosis (RBN) by synthesizing various treatment modalities. While prior coverage has addressed specific uses of bevacizumab in other contexts, such as its lack of additional benefit when added to serplulimab plus chemotherapy in nsq-NSCLC, this review focuses specifically on RBN management. It provides a comprehensive overview of the role of bevacizumab and advanced radiotherapy for patients with intracranial and head and neck malignancies.
When patients undergo radiation for head and neck cancers, they face a serious risk: radiation-induced brain necrosis. This is a condition where the brain tissue dies because of the radiation used to fight tumors. It happens due to blood vessel damage and inflammation in the brain.
Recent reviews show several ways to manage this risk. Doctors can use advanced radiation techniques like IMRT or FLASH, which aim to target tumors more precisely while protecting healthy tissue. They are also looking at medications like bevacizumab and corticosteroids to help protect the brain and reduce swelling.
Other options include hyperbaric oxygen therapy and specialized procedures like LITT. Because this is a narrative review of existing research rather than a new clinical trial, these findings provide a roadmap for doctors to choose the best tools for their patients. Early detection through advanced imaging also helps catch issues before they become severe.
What this means for you:
Newer radiation techniques and specific medications offer more ways to protect brain tissue during cancer treatment.
Common questions
What causes brain tissue to die during radiation therapy?
The damage is primarily caused by injury to blood vessels and inflammation in the brain. Specifically, problems with oxygen levels and certain proteins like HIF-1α and VEGF cause these issues. These factors lead to tissue death after a patient receives radiation for head or neck cancers.
What treatments are available for this condition?
Doctors can use several options depending on the patient's needs. These include medications like corticosteroids and bevacizumab, as well as procedures like hyperbaric oxygen therapy (HBOT) or laser-based treatments (LITT). Advanced radiation techniques like IMRT and FLASH also help protect healthy tissue.
How is brain damage detected early?
Doctors use specialized imaging tools to spot issues early. These include MRS, PWI, and PET/CT scans. Identifying the problem early allows for better management of radiation-induced brain necrosis during the course of cancer treatment.
Radiation-induced brain necrosis (RBN) is a serious and often debilitating complication of radiotherapy for intracranial and head and neck malignancies, with an incidence of 5–25%. It can lead to significant cognitive impairment, neurological deficits, and increased mortality. As radiotherapy techniques advance and patient survival improves, effective prevention and management of RBN have become critical clinical priorities. This review systematically summarizes the current understanding of RBN pathogenesis, highlighting the central roles of vascular injury (endothelial damage, HIF-1α/VEGF dysregulation) and neuroinflammation (microglial activation, cytokine release). We discuss recent advances in preventive strategies, including refined radiotherapy modalities such as intensity-modulated radiotherapy (IMRT), fractionated stereotactic radiosurgery (fSRS), and FLASH ultra-high-dose-rate radiotherapy, as well as pharmacological prophylaxis using bevacizumab and neuroprotective agents (NGF, GM1, edaravone). Established and emerging treatment options are reviewed, including corticosteroids, bevacizumab, hyperbaric oxygen therapy (HBOT), laser interstitial thermal therapy (LITT), and Colony Stimulating Factor 1 Receptor(CSF1R) inhibitors. We also cover innovations in imaging for early detection and differential diagnosis, including magnetic resonance spectroscopy (MRS), perfusion-weighted imaging (PWI), and Positron Emission Tomography-Computed Tomography(PET/CT) with advanced tracers (11C-methionine, 18F-FET). Finally, we summarize updates to international management guidelines, particularly the 2022 DEGRO guidelines, and propose future directions for research and therapeutic optimization.
